Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings GrowthZacks Investment Research • Thursday
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates TranscriptSeeking Alpha • Tuesday
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of DirectorsBusiness Wire • Tuesday
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026GlobeNewsWire • 10/24/26
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3GlobeNewsWire • 10/23/26
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance BiopharmaGlobeNewsWire • 10/19/26
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial ResultsGlobeNewsWire • 10/15/26
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 OutlookMarketBeat • 10/02/26
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma AcquisitionGlobeNewsWire • 09/28/26
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera ApprovalSeeking Alpha • 08/27/26
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric CancerZacks Investment Research • 08/26/26
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsGlobeNewsWire • 08/06/26